Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson’s disease

[1]  J. Santamaria,et al.  Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases , 2022, Movement disorders : official journal of the Movement Disorder Society.

[2]  R. Fernández-Santiago,et al.  What have we learned from genome-wide association studies (GWAS) in Parkinson's disease? , 2022, Ageing Research Reviews.

[3]  E. Tolosa,et al.  Differential Phospho‐Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease , 2022, Movement disorders : official journal of the Movement Disorder Society.

[4]  J. Infante,et al.  Serial DaT‐SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years’ follow‐up , 2021, European journal of neurology.

[5]  A. Toga,et al.  RNA sequencing of whole blood reveals early alterations in immune cells and gene expression in Parkinson’s disease , 2021, Nature Aging.

[6]  Sonja W. Scholz,et al.  Challenges in the diagnosis of Parkinson's disease , 2021, The Lancet Neurology.

[7]  D. Galasko,et al.  Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson’s disease progression , 2021, Nature Aging.

[8]  Matthieu Drouyer,et al.  LRRK2 Phosphorylation, More Than an Epiphenomenon , 2020, Frontiers in Neuroscience.

[9]  J. Ferreira,et al.  Circulating Inflammatory miRNAs Associated with Parkinson’s Disease Pathophysiology , 2020, Biomolecules.

[10]  H. Berendse,et al.  CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers , 2020, Translational Neurodegeneration.

[11]  E. Tolosa,et al.  LRRK2 in Parkinson disease: challenges of clinical trials , 2020, Nature Reviews Neurology.

[12]  M. Stamelou,et al.  Circulating Brain‐Enriched MicroRNAs for Detection and Discrimination of Idiopathic and Genetic Parkinson's Disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[13]  Ru-jing Ren,et al.  miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson’s disease , 2019, Cell Death & Disease.

[14]  M. Dominguez,et al.  PI3K/Akt Cooperates with Oncogenic Notch by Inducing Nitric Oxide-Dependent Inflammation. , 2018, Cell reports.

[15]  K. Marder,et al.  Progression in the LRRK2-Asssociated Parkinson Disease Population , 2018, JAMA neurology.

[16]  R. Lyle,et al.  A comprehensive profile of circulating RNAs in human serum , 2017, bioRxiv.

[17]  J. Infante,et al.  Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease , 2017, Neurology.

[18]  Zishan Wang,et al.  Downregulation of blood serum microRNA 29 family in patients with Parkinson’s disease , 2017, Scientific Reports.

[19]  E. Tolosa,et al.  Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry , 2017, Movement disorders : official journal of the Movement Disorder Society.

[20]  J. Schwamborn,et al.  Parkinson’s Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32 , 2017, Molecular Neurobiology.

[21]  Xusheng An,et al.  MicroRNA biomarkers of Parkinson’s disease in serum exosome-like microvesicles , 2017, Neuroscience Letters.

[22]  Meir Kestenbaum,et al.  Clinical Features of LRRK2 Carriers with Parkinson's Disease. , 2017, Advances in neurobiology.

[23]  A. Ascherio,et al.  The epidemiology of Parkinson's disease: risk factors and prevention , 2016, The Lancet Neurology.

[24]  Chao Wang,et al.  Serum miR‐221 serves as a biomarker for Parkinson's disease , 2016, Cell biochemistry and function.

[25]  M. Ciotti,et al.  Therapeutic effects of the Rho GTPase modulator CNF1 in a model of Parkinson’s disease , 2016, Neuropharmacology.

[26]  E. Tolosa,et al.  Motor and nonmotor heterogeneity of LRRK2‐related and idiopathic Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[27]  S. Sveinbjornsdottir.  The clinical symptoms of Parkinson's disease , 2016, Journal of neurochemistry.

[28]  J. Sainz,et al.  Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S–associated Parkinson's disease , 2016, Neurobiology of Aging.

[29]  Xi Chen,et al.  Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease. , 2016, Parkinsonism & related disorders.

[30]  A. Elbaz,et al.  Epidemiology of Parkinson's disease. , 2016, Revue neurologique.

[31]  Y. Gui,et al.  Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease , 2015, Oncotarget.

[32]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[33]  H. Kiyonari,et al.  The Parkinson’s Disease-Associated Protein Kinase LRRK2 Modulates Notch Signaling through the Endosomal Pathway , 2015, PLoS genetics.

[34]  K. Marder,et al.  Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium , 2015, Neurology.

[35]  E. Tolosa,et al.  MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder , 2015, Annals of neurology.

[36]  S. Retta,et al.  Cerebral cavernous malformation (CCM) disease: from monogenic forms to genetic susceptibility factors. , 2015, Journal of neurosurgical sciences.

[37]  B. Osborne,et al.  Notch signaling regulates the phosphorylation of Akt and survival of lipopolysaccharide-activated macrophages via regulator of G protein signaling 19 (RGS19). , 2014, Immunobiology.

[38]  M. Farrer,et al.  LRRK2 parkinsonism in Tunisia and Norway: A comparative analysis of disease penetrance , 2014, Neurology.

[39]  J. Molinuevo,et al.  Identification of blood serum micro‐RNAs associated with idiopathic and LRRK2 Parkinson's disease , 2014, Journal of neuroscience research.

[40]  Gunhild Waldemar,et al.  The potential of microRNAs as biofluid markers of neurodegenerative diseases – a systematic review , 2014, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[41]  N. Lamarche‐Vane,et al.  Rho GTPases in neurodegeneration diseases. , 2013, Experimental cell research.

[42]  O. Combarros,et al.  High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson's disease patients in Cantabria (Spain) , 2011, Movement disorders : official journal of the Movement Disorder Society.

[43]  E. Martin,et al.  Convergence of miRNA Expression Profiling, α-Synuclein Interacton and GWAS in Parkinson's Disease , 2011, PloS one.

[44]  J. Molinuevo,et al.  Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study , 2011, The Lancet Neurology.

[45]  B. Lask,et al.  Implications for Treatment , 2011 .

[46]  Pasko Rakic,et al.  Not(ch) just development: Notch signalling in the adult brain , 2011, Nature Reviews Neuroscience.

[47]  B. Wolozin,et al.  Rac1 Protein Rescues Neurite Retraction Caused by G2019S Leucine-rich Repeat Kinase 2 (LRRK2)* , 2011, The Journal of Biological Chemistry.

[48]  A. Gorostidi,et al.  Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain) , 2010, Movement disorders : official journal of the Movement Disorder Society.

[49]  N. Sokol,et al.  Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression , 2010, Nature.

[50]  E. Tolosa,et al.  Molecular and clinical prodrome of Parkinson disease: implications for treatment , 2010, Nature Reviews Neurology.

[51]  K P Bhatia,et al.  The role of DAT-SPECT in movement disorders , 2008, Journal of Neurology, Neurosurgery & Psychiatry.

[52]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[53]  A. Brice,et al.  Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.

[54]  D. Jennings,et al.  Can we image premotor Parkinson disease? , 2009, Neurology.

[55]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[56]  E. Tolosa,et al.  Role of DAT‐SPECT in the diagnostic work up of Parkinsonism , 2007 .

[57]  J. Manson,et al.  Prospective Study of , 2007 .

[58]  E. Tolosa,et al.  LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. , 2006, Archives of neurology.

[59]  Mathias Toft,et al.  Clinical features of LRRK2‐associated Parkinson's disease in central Norway , 2005, Annals of neurology.

[60]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[61]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[62]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[63]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[64]  Anirvan Ghosh,et al.  The role of Notch and Rho GTPase signaling in the control of dendritic development , 2001, Current Opinion in Neurobiology.

[65]  Helena C. Kraemer,et al.  Risk factors and prevention , 2000 .

[66]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[67]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.